Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

has been shown to safely and effectively help keep people from developing preventable blood clots," said Alan Brownstein, Chief Executive Officer of the National Blood Clot Alliance. "The FDA approval of a new blood thinner, XARELTO®, offers a new option for patients seeking knee or hip replacement surgery, and we encourage people to discuss with their physicians the risk of blood clots and which blood thinner offers optimal protection as part of their pre-surgical consultation."

Pivotal data from the XARELTO® Phase 3 clinical development program reflected in the approved label showed significantly greater efficacy of rivaroxaban, both in head-to-head comparison with enoxaparin and when comparing extended-duration (5 weeks) rivaroxaban with short-duration (2 weeks) enoxaparin, followed by placebo. In these trials, rivaroxaban and enoxaparin demonstrated similar safety profiles including low rates of major bleeding.

XARELTO® is approved for use at a 10 mg dose, once-daily for 35 days following hip replacement and for 12 days following knee replacement surgery. To date, XARELTO® is approved in more than 110 countries worldwide and has been successfully launched in more than 80 countries by Bayer HealthCare. Janssen Pharmaceuticals, Inc. holds marketing rights for XARELTO® in the U.S. The U.S. Bayer HealthCare sales force will support the Janssen Pharmaceuticals, Inc. sales force by detailing XARELTO® in designated hospital accounts.

"Shorter hospital stays following hip and knee replacement surgeries have made the prevention of venous blood clots an outpatient issue, and XARELTO® provides a safe and effective oral treatment option that can be easily transitioned from use in hospital to home," said Paul Chang, M.D., Vice President, Medical Affairs, Internal Medicine, Janssen Pharmaceuticals, Inc. "We're pleased to make XARELTO® tablets available to physicians to help them better protect their patient
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , , ... Group (MRG), the global authority on medical technology market intelligence, ... enteral feeding devices will be a key driver of the ... MRG,s new US and European Markets for Enteral Feeding ...
... , FORT COLLINS, Colo., Dec. 14 ... 250 mg (chenodiol tablets). On October 22, 2009, ... an important therapy for patients suffering from gallstones in ... disease or advanced age. , Chenodal prescriptions have started ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... evidence mounts showing the potential health benefits of probiotics, ... are taking supplements. And the chemical industry is getting ... health effects could deter growth, so the industry is ... according to the cover story in Chemical & ... the American Chemical Society. , Melody M. Bomgardner, a ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Mothers, exposure during pregnancy to a class of air ... problems in their children. PAH are,released to air during ... coal, and other,organic material. , The study is the ... problems among school‐age children and two complementary measures of ...
... 21 (HealthDay News) -- Alzheimer,s disease and other types of ... brain, new research indicates. The findings from MRI brain ... to use MRI to predict the progression of dementias and ... San Francisco (UCSF) researchers said. They found that Alzheimer,s ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay ... treatments, alternative therapies such as acupuncture, acupressure and dietary ... sinusitis, a new pilot study suggests. The authors ... explore the potential of combining Western medicine with Eastern ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... epidemic to the United States and the economic value of ... to a new report. The problem is that estimates ... out only 10 years, while it may take much longer ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay News) ... in people already taking statins such as Lipitor, making ... alternative, a preliminary new study suggests. Two single-dose ... a group with high cholesterol showed that the drug, ...
... led by A. K. Rajasekaran, PhD, Director of the Nemours ... protein involved in cell function and regulation is stopped by ... published online in the American Journal of Physiology - ... is well recognized as a cause of lung cancer and ...
Cached Medicine News:Health News:Prenatal exposure to combustion-related pollutants and anxiety, attention problems in young children 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 3Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 2Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 3Health News:Statin Alternative Looks Promising in Early Trials 2Health News:Statin Alternative Looks Promising in Early Trials 3Health News:Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke 2
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: